FROM THE LAB
Research & Insights
View all articlesRetatrutide Compounding After FDA Warning Letters: 503A Limits and State Board Actions in 2026
FDA warning letters and state board actions in 2026 have reshaped retatrutide compounding. 503A pharmacies face new l...
Read ArticleFDA Panel's Six-Peptide Endorsement Creates New Compounding Gray Area for Tesamorelin: How 503A Pharmacies Navigate Off-Label Prescribing and Quality Control After the 2026 Decision
The 2026 FDA panel endorsement of six peptides creates a compounding gray area for tesamorelin. 503A pharmacies face ...
Read ArticleTesamorelin FDA Inspection Findings at 503B Outsourcing Facilities: A Compliance Timeline for Compounding Pharmacies
The FDA has intensified inspections of 503B facilities compounding tesamorelin, uncovering stability, lyophilization,...
Read Article